Stock Analiz

Cumberland Pharmaceuticals Inc. CPIX

Biotechnology: Pharmaceutical Preparations · IPO 2009 · data as of November 13, 2026

$5.88Market cap $88M
Open the interactive analysis →

Cumberland Pharmaceuticals Inc. (CPIX) is a healthcare company listed in the US with a market value of about $88M. In the twelve months to September 30, 2026 it had revenue of $34M and net income of $69M, a net margin of 203.7%.

Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (3/5); the weakest is track record (0/5).

Key numbers: a P/E of 1.3, 5-year revenue growth of 4% a year, a 5-year average ROIC of -11%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 3% below the current price.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2009. Revenue went from $37M in 2014 to $45M in 2025, growth of about 1.7% a year. It was profitable in 0 of the last 10 years in our data. It spends 13% of revenue on research and development.

Score: 1.4 / 5

Value2/5
Future growth3/5
Track record0/5
Financial health1/5
Shareholder returns1/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year revenue growth above 8% a year
  • 5-year average ROIC above 12%

Valuation

P/E (TTM)1.3
Forward P/E—
P/FCF—
P/S2.6
P/B1.2
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-1.1%
Shareholder yield0.3%
Intrinsic value vs. price−3%

Growth and quality

Revenue growth (1 yr)17.6%
Revenue growth (5 yrs, per year)3.5%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)-16.7%
Net margin (5-yr avg.)-12.5%
ROIC (5-yr avg.)-11.0%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$34M$45M$38M$40M$42M$36M$37M$34M$29M$41M$33M
Net income$69M-$3M-$6M-$6M-$6M-$4M-$3M-$4M-$7M-$8M-$944683
Free cash flow-$987321$5M-$678647$6M$8M$6M$5M$3M$3M-$833674$438606
EPS (diluted)$4.47$-0.19$-0.46$-0.44$-0.38$-0.24$-0.22$-0.23$-0.45$-0.50$-0.06
Net margin203.7%-6.4%-17.1%-15.9%-13.3%-9.8%-8.9%-10.3%-23.7%-19.4%-2.9%
ROIC—-6.3%-14.8%-15.7%-7.9%-10.3%-7.9%-12.7%-11.6%-4.4%-1.4%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

What is Cumberland Pharmaceuticals’s P/E ratio?

About 1.3, based on the last twelve months of diluted earnings per share.

Is Cumberland Pharmaceuticals stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 3% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Cumberland Pharmaceuticals pay a dividend?

Not currently.

Is Cumberland Pharmaceuticals a good stock to buy?

We do not give buy or sell advice. Cumberland Pharmaceuticals scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.